Medidata appoints Lisa Moneymaker as chief strategy officer
Ella Day | August 13, 2025 | Appointment | Clinical Trial Services, Research and Development | Corporate, Medidata, chief strategy officer
Medidata has appointed Lisa Moneymaker as chief strategy officer to support the company’s long-term growth in the life sciences technology sector.
Moneymaker will lead the strategy team, focusing on product innovation, AI-driven clinical trial solutions and the use of research insights to anticipate market trends. The role forms part of a broader business transformation aimed at strengthening the company’s position in a rapidly changing market.
With 25 years’ experience in tech-enabled clinical development, Moneymaker’s previous roles span the pharma, biotech and medical device sectors. Before taking on her new responsibilities, she served as senior vice-president for strategic customer engagement at Medidata.
“The strategy organisation signifies our unwavering dedication to implementing innovative solutions, reflecting the belief that a strategy rooted in customer needs and mission is necessary for our success in contributing towards the advancement of the broader industry,” said Anthony Costello, Medidata’s chief executive. “Lisa’s proven leadership within the field and profound grasp of the intricate relationship between technology and clinical research perfectly align with our strategic imperatives and future vision.”
Headquartered in New York City, US and part of Dassault Systèmes, Medidata provides digital solutions to support clinical trials and says it has worked on more than 36,000 studies involving over 11 million patients. The company’s platform is used by around 2,300 customers worldwide.
Ella Day
13/8/25
Related Content
Medidata launches programme to accelerate therapy delivery
Medidata has announced the launch of its Medidata Site Insights Program – a collection of …
Medidata and Sanofi Vaccines extend collaboration
Medidata and Sanofi Vaccines have announced a collaboration utilising Medidata electronic clinical outcome assessment (eCOA) …
Visions for the future: FT pharma and biotech event
The FT Global Pharmaceutical and Biotechnology Conference held in London recently asked: “What will the …
